Adverse Effects

Biomarkers

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Melanoma

Mesothelioma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Clinical Topics

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Breaking Barriers

Face Off

From All Angles

Meeting of the Minds

Morning Rounds

OncView

Podcasts

Readout 360

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Spotlight

Around the Practice 

Journal

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Evolving Landscape of Glioma: A Focus on IDH-Mutant Gliomas

Video Series

INDIGO Trial: Examining IDH-Mutant Low-Grad Gliomas

How might the results of the INDIGO trial and the approval of vorasidenib influence treatment decisions for IDH-mutant low-grade gliomas?

What factors would you consider when evaluating these new treatment options for patients?

Videos

Vinay K. Puduvalli, MD, explores recent advances in glioma classification and treatment, discussing the impact of new WHO guidelines, molecular markers, clinical trials, and emerging therapies like IDH inhibitors on patient care strategies, while identifying persisting challenges and future research priorities in neuro-oncology.

Panelists discuss how the updated WHO classification system for gliomas has impacted their treatment approaches, while also addressing the practical difficulties of integrating these changes into routine clinical care.

Real-World Clinical Practice: Challenges With Glioma Management

Panelists discuss how they tailor treatment strategies for oligodendrogliomas and Grade 2 gliomas based on key clinical and molecular markers, with particular attention to insights from the CODEL trial and RTOG 9802 study.

Treatment Approaches for Patients With Oligodendrogliomas and Grade 2 Gliomas

Panelists discuss how they determine the optimal timing of temozolomide administration - concurrent or adjuvant - for WHO grade 3 astrocytomas lacking 1p/19q codeletion, drawing on evidence from the CATNON trial to inform their decision-making process.

CATNON Trial: Concurrent Versus Adjuvant Temozolomide in Treating WHO Grade 3 Astrocytomas Without 1p/19q Codeletion

Panelists discuss how IDH inhibitors such as ivosidenib could potentially reshape the treatment approach for low-grade gliomas, while also exploring what further clinical evidence would be necessary to confidently integrate these novel agents into standard care protocols.

IDH Inhibitors in the Treatment of Low-Grade Gliomas

Panelists discuss how the INDIGO trial results and vorasidenib's approval could shift treatment paradigms for IDH-mutant low-grade gliomas, weighing various clinical, molecular, and patient-specific factors when considering the integration of this novel targeted therapy into individualized treatment plans.

Panelists discuss how unmet needs in glioma treatment persist despite recent advances, highlighting key areas for future research and development to improve outcomes and quality of life for patients with gliomas.

Closing Thoughts and Unmet Needs in Glioma Treatment

INDIGO Trial: Examining IDH-Mutant Low-Grad Gliomas

EP: 1.Real-World Clinical Practice: Challenges With Glioma Management

EP: 2.Treatment Approaches for Patients With Oligodendrogliomas and Grade 2 Gliomas

EP: 3.CATNON Trial: Concurrent Versus Adjuvant Temozolomide in Treating WHO Grade 3 Astrocytomas Without 1p/19q Codeletion

EP: 4.IDH Inhibitors in the Treatment of Low-Grade Gliomas

EP: 5.INDIGO Trial: Examining IDH-Mutant Low-Grad Gliomas

EP: 6.Closing Thoughts and Unmet Needs in Glioma Treatment